Amylyx Pharmaceuticals, Inc. Share Price & Technical Analysis
AMLX · $13.58 (-2.51%)
Healthcare / Drug Manufacturers - Specialty & Generic
$13.58
-2.51%
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and …
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
-16% return in May, -6% avg return in past 3 year May month.
15% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 19% | 6% | -7% | 13% | -16% | – | – | – | – | – | – | – | 15% |
| 25 | -3% | -6% | 6% | 46% | 2% | 23% | 25% | 19% | 48% | 4% | 8% | -18% | 154% |
| 24 | 9% | 18% | -85% | -36% | -6% | 12% | 11% | 10% | 45% | 69% | 2% | -31% | 18% |
| 23 | 5% | -11% | -16% | -3% | -13% | -12% | 8% | -8% | -16% | -11% | -12% | 4% | -86% |
| 22 | 10% | 42% | -61% | -25% | 0% | 114% | 43% | -7% | 12% | 24% | 6% | -5% | 155% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.60B
P/E ratio
—
52W high
$18.61
52W low
$4.64
Volume
8,18,486
Beta
-0.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Amylyx Pharmaceuticals, Inc. share price today?
- Amylyx Pharmaceuticals, Inc. (AMLX) last traded around $13.58 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AMLX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AMLX. Download the app for real-time alerts.
- How can I analyze Amylyx Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.